BioSpace News Archive

SalioGen Therapeutics, a privately held biotechnology company developing Gene Coding™, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series B financing.

Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop vaccines against infectious diseases, announced the appointment of John Shiver, Ph.D., to its Board of Directors.

Entrada Therapeutics, Inc., a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle therapeutics as a new class of medicines, announced that Jared Cohen, PhD, JD has been appointed General Counsel, effective immediately.

LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic conditions, today announced that R. Nolan Townsend, Chief Executive Officer of LEXEO Therapeutics, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference.

F-star Therapeutics, Inc. (NASDAQ: FSTX), today announced that Ares Trading S.A., an affiliate of Merck KGaA, Darmstadt, Germany has exercised a fourth licensing option to develop another bispecific program under the ongoing immuno-oncology collaboration.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today provided a corporate update available on the Company’s website.

Autolus Therapeutics plc today announced that they are scheduled to deliver a corporate presentation at the following virtual conferences: Dr. Christian Itin, Chief Executive Officer, will present at the 40th annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 8.15 am ET.

FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced Boyd Clarke, Executive Chairman is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference.

NuVasive, Inc. (NASDAQ: NUVA), today announced the Company received U.S. Food and Drug Administration (FDA) 510(k) clearance for expanded indications of use for Attrax® Putty with its comprehensive thoracolumbar interbody portfolio for spine surgery.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have completed the collaboration transaction between the two companies.